BOULDER, Colo. (AP) Clovis Oncology Inc. (CLVS) reported a $99 million loss in its fourth quarter on Tuesday.
It had a loss of $1.02 per share, the Boulder, Colorado-based company said. Losses, adjusted for non-recurring costs, came to 74 cents per share.
Wall Street expectations were beaten by the results. Zacks Investment Research’s average estimate of five analysts surveyed was a loss of 76 cents per share.
In the period, the biopharmaceutical company reported revenues of $43.3 million, which also beat Street’s projections. $43.2 million was expected by four analysts surveyed by Zacks.
The company reported for the year that its loss fell to $369.2 million, or $4.38 per share. The income was reported to be $164.5 million.
Since the beginning of the year, Clovis shares have risen 39 percent. In the last 12 months, the stock has declined 38 percent.